No results for ‘’
Mankind Pharma Ltd
NSE: MANKIND BSE: 543904
₹2469.60
(4.13%)
Tue, 04 Aug 2026, 02:23 pm
Market Cap (in Cr)102005.87
PE Ratio49.97
Dividend0.04
Health Technology
Pharmaceuticals: Major
24.5KMankind Pharma Cashflow
| Particulars | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Deprecation and amortization | -990.51M | -1.19B | -1.67B | -3.26B | -3.78B | -6.21B |
| Accumulated depreciation, total | -3.52B | -4.45B | -5.76B | -7.33B | -9.48B | -11.38B |
| Cash from operating activities | 10.67B | 11.92B | 9.15B | 17.85B | 21.67B | 23.85B |
| Funds from operations | 12.07B | 12.57B | 15.02B | 16.18B | 21.85B | 25.31B |
| Net income (cash flow) | 10.30B | 12.65B | 14.33B | 12.82B | 19.13B | 19.91B |
| Depreciation & amortization (cash flow) | 990.51M | 1.19B | 1.41B | 3.26B | 3.98B | 6.21B |
| Depreciation/depletion | 907.21M | 1.05B | 1.41B | 1.67B | 2.36B | 2.59B |
| Amortization | 83.30M | 140.90M | 550.00K | 1.59B | 1.62B | 3.62B |
| Deferred taxes (cash flow) | 0 | 0 | 0 | 0 | 0 | 0 |
| Non-cash items | -3.29B | -5.54B | -6.14B | -3.79B | -6.11B | -6.15B |
| Changes in working capital | -1.40B | -650.29M | -5.86B | 1.67B | -175.70M | -1.46B |
| Cash from investing activities | -4.56B | -12.57B | -13.82B | -10.67B | -21.22B | -127.51B |
| Capital expenditures | -2.28B | -3.08B | -23.46B | -8.32B | -3.89B | -5.31B |
| Capital expenditures - fixed assets | -2.28B | -3.08B | -4.65B | -7.89B | -3.22B | -4.71B |
| Capital expenditures - other assets | 0 | 0 | -18.81B | -430.49M | -670.00M | -593.20M |
| Cash from financing activities | -5.05B | 1.06B | 6.22B | -6.98B | 306.50M | 103.29B |
| Free cash flow | 8.39B | 8.83B | 4.51B | 9.96B | 18.45B | 19.13B |